0000000000483029

AUTHOR

Stefano Partelli

0000-0001-8938-6170

showing 3 related works from this author

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

2019

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

Liver metastasemedicine.medical_specialtyPathologySocio-culturale03 medical and health sciencesLiver metastasesRare Diseases0302 clinical medicineLiver metastases ; Neuroendocrine tumours ; Pancreas ; Rare cancersNeuroendocrine tumoursMultidisciplinary approachRare DiseaseNeuroendocrine tumourHumansMedicinePancreaRare cancersPrecision MedicineIntensive care medicinePancreasLiver metastases Neuroendocrine tumours Pancreas Rare cancersPatient Care Teambusiness.industryPancreatic NeoplasmRare cancerGeneral MedicinePancreatic NeoplasmsSurvival RateNeuroendocrine TumorsLiver metastases; Neuroendocrine tumours; Pancreas; Rare cancers; Surgery; OncologyOncology030220 oncology & carcinogenesisMandate030211 gastroenterology & hepatologySurgerybusinessNeuroendocrine TumorDelivery of Health CareHuman
researchProduct

The treatment of hyperinsulinemic hypoglycaemia in adults: an update

2016

Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH. A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed. One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH. New approaches to treatment of HH are available including mini-invasive sur…

Adultmedicine.medical_specialtyPediatricsendocrine system diseasesEndocrinology Diabetes and MetabolismGastric bypassNesidioblastosis030209 endocrinology & metabolismHypoglycemiaSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyHyperinsulinismmedicineHyperinsulinemic hypoglycaemiaHumansAutoimmune hypoglycaemiaInsulinomaEverolimusbusiness.industryAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; HypoglycemiaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; Hypoglycemia; Endocrinology Diabetes and Metabolism; EndocrinologySettore MED/13 - ENDOCRINOLOGIANesidioblastosimedicine.diseaseHypoglycemiaSurgeryDiabetes and MetabolismTreatmentNesidioblastosisAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment030220 oncology & carcinogenesisAutoimmune hypoglycaemiaInsulinomaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Endocrinology Diabetes and Metabolism; EndocrinologyDifferential diagnosisbusinessHyperinsulinismhormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

2018

Abstract Introduction Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th–75th IQR). Results Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3…

0301 basic medicineIndolesEndocrinology Diabetes and MetabolismNeuroendocrine tumorsPyrroleGastroenterologyTarget therapyEfficacyAntineoplastic Agent0302 clinical medicineEndocrinologyRetrospective StudieSunitinibPancreadiabetes and metabolismSunitinibGastroenterologyPancreatic NeoplasmMiddle AgedDiabetes and MetabolismNeuroendocrine TumorsTreatment OutcomeTolerabilityNeuroendocrine tumors; Pancreas; Progressive disease; Sunitinib; Target therapy; Endocrinology Diabetes and Metabolism; Hepatology; EndocrinologyItaly030220 oncology & carcinogenesisNeuroendocrine tumorsmedicine.drugHumanAdultmedicine.medical_specialtyAntineoplastic AgentsNeutropenia03 medical and health sciencesNeuroendocrine tumorInternal medicinemedicineHumansPyrrolesProgression-free survivalPancreasCancer stagingAgedRetrospective StudiesHepatologybusiness.industryProgressive diseasemedicine.diseasePancreatic Neoplasms030104 developmental biologyNeuroendocrine tumors; pancreas; progressive disease; Sunitinib; target therapy; endocrinology; diabetes and metabolism; hepatology; endocrinologyIndolebusinessProgressive diseasePancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct